Madison Simons

Madison Simons

Auto-generated profile, based on publicly available information

Madison Simons

Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
MSMadison Simons
Madison Simons
TTTiffany Taft
Tiffany Taft
BDBethany Doerfler
Bethany Doerfler
JRJohannah S. Ruddy
Johannah S. Ruddy
SBSteven Bollipo
Steven Bollipo
MTMiranda A. L. van Tilburg
Miranda A. L. van Tilburg

1 August 2021 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
TTTiffany Taft
Tiffany Taft
MCMeredith R. Craven
Meredith R. Craven
EAEmerald P. Adler
Emerald P. Adler
MSMadison Simons
Madison Simons
LNLinda Nguyen
Linda Nguyen

1 April 2022 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
LGLivia Guadagnoli
Livia Guadagnoli
MSMadison Simons
Madison Simons
JMJosie McGarva
Josie McGarva
TTTiffany Taft
Tiffany Taft
Miranda Van TilburgMiranda Van Tilburg
Miranda Van Tilburg
Gastroesophageal reflux disease (GERD) is a common gastrointestinal illness with symptoms of heartburn, chest pain, and regurgitation. Management of GERD can involve medication use, lifestyle modification (eg, dietary modification), and surgical intervention depending on the individual patient and disease severity. Poor adherence to medication and recommended lifestyle changes may result in increased symptom severity and decreased quality of life. This paper aimed to systematically review the literature on lifestyle modification for the management of GERD. Fourteen articles were included based on search criteria. Following review and analysis, three types of lifestyle modifications were present in the literature and include medication use, dietary recommendations, and sleep recommendations. Despite being a pharmacological treatment, medication adherence was included in the review, as health behavior change can be used to improve adherence. Overall, the factors associated with adherence to modifications varied in terms of impact and directionality, depending on the type of lifestyle modification. Symptom severity emerged as important across all lifestyle modifications, and is associated with increased adherence to medication use, but decreased adherence to dietary guidelines. While patient–provider communication appeared to improve patient knowledge, it is unclear if increased knowledge translates to improved adherence. The review also demonstrated a lack of clear and standardized guidelines across lifestyle modifications, which may have an influence on adherence and adherence reporting. Future research in GERD treatment adherence would benefit from the use of validated measures to assess adherence. Specific recommendations to improving patient adherence are discussed.

19 March 2024 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
MSMadison Simons
Madison Simons
MCMichael Cline
Michael Cline
AGAshley Gubbels
Ashley Gubbels
CKCara King
Cara King
ALAnthony Lembo
Anthony Lembo
SLStephen Lupe
Stephen Lupe
Endometriosis is a chronic inflammatory disease affecting 10%-15% of women, with symptoms including abdominopelvic pain, dysmenorrhea, and menorrhagia. Up to 90% experience gastrointestinal (GI) symptoms including constipation, bloating, and nausea/vomiting.1 Females with endometriosis are at 3-5 times greater risk of developing IBS than healthy women,2,3 with rates of IBS as high as 52%.4 Another study demonstrated 37% of those with IBS also had endometriosis, much higher than the typical prevalence of endometriosis.5 Patients with IBS and endometriosis experience lower pain thresholds and more painful menstrual cycles than those with either condition alone. This amplification of pain experiences can increase health care utilization and decrease quality of life.

17 September 2024 in Journal of Human Nutrition and Dietetics
Verified
Journal Article
Open access
MSMadison Simons
Madison Simons
JMJosie McGarva
Josie McGarva
BDBethany Doerfler
Bethany Doerfler
KTKathryn Tomasino
Kathryn Tomasino
APAnjali Pandit
Anjali Pandit
TTTiffany Taft
Tiffany Taft
Background: Food‐related quality of life (FRQoL) measures the impact of diet, eating behaviours and food‐related anxiety on quality of life. Patients often view food and eating as central to symptom management. This is the first study to examine FRQoL in patients with inflammatory bowel disease, celiac sprue, achalasia and eosinophilic oesophagitis.Methods: A total of 289 adults aged ≥18 years completed self‐report measures evaluating the use of dietary treatment, FRQoL and other psychosocial outcomes. Principal component factor analysis evaluated potential subscales within the Food‐Related Quality of Life Scale (FRQoL‐29), to date validated only with a total score. Univariate analyses investigated differences in FRQoL based on diagnosis, whereas correlations and hierarchical regression identified relationships between FRQoL and psychosocial outcomes.Results: Factor analysis revealed four subscales within the FRQoL‐29, with hypervigilance around eating being the primary driver in total score. Patients reported substantial impacts of FRQoL, with those not using diet therapy scoring significantly higher for FRQoL than those on a diet with and without the support of a registered dietitian (RD). Both social (r = 0.41, p < 0.001) and physical (r = 0.31, p < 0.001) domains of health‐related quality of life were higher in patients with greater FRQoL.Conclusion: FRQoL is significantly degraded in patients with organic gastrointestinal illness diseases, and hypervigilance around food appears to contribute most to this. Use of dietary treatment and meeting with an RD were associated with lower FRQoL, though it is unclear if patients sought RD assistance before FRQoL declined. Future studies on the relationship between dietary treatment, RD support and FRQoL are warranted.

11 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
RKRidhima Kaul
Ridhima Kaul
CJClaire Jansson-Knodell
Claire Jansson-Knodell
MSMadison L. Simons
Madison L. Simons
KWKendra Weekley
Kendra Weekley
DGDavid Gardinier
David Gardinier
ARAlberto Rubio-Tapia
Alberto Rubio-Tapia
Celiac disease (CeD) is an autoimmune disorder where adherence to a lifelong gluten-free diet (GFD) is the only available treatment. While this approach is rather effective, some patients experience ongoing symptoms, and this factor, along with the rigidity of the GFD, may predispose some to disordered eating behaviors, including Avoidant/Restrictive Food Intake Disorder (ARFID). ARFID is characterized by persistent food avoidance that is not driven by body image concerns, resulting in nutritional, psychological, and social impairment. This scoping literature review explores the emerging intersection between ARFID and CeD, examining prevalence, pathophysiology, clinical features, complications, and management strategies. Recent studies report that 14–57% of individuals with CeD may meet the criteria for ARFID, depending on the population and screening tools used. Factors contributing to ARFID in CeD may include ongoing gastrointestinal symptoms, anxiety over gluten exposure, negative conditioned responses to food, social challenges related to GFD adherence, and psychiatric co-morbidities. ARFID in CeD is associated with worsened nutritional deficiencies, anxiety, depression, and impaired social functioning, making the diagnosis of ARFID challenging due to symptom overlap with CeD and other psychiatric conditions. Management requires a multidisciplinary approach, including medical, nutritional, and psychological interventions. Routine screening, early intervention, and integrated care models may improve outcomes and quality of life.